Literature DB >> 2346237

Nonallergic rhinitis with eosinophilia syndrome a precursor of the triad: nasal polyposis, intrinsic asthma, and intolerance to aspirin.

D A Moneret-Vautrin1, V Hsieh, M Wayoff, J L Guyot, C Mouton, Y Maria.   

Abstract

Fifty-two cases of perennial rhinitis were studied, leading to the diagnosis of seven cases of nonallergic rhinitis with eosinophilia syndrome (NARES) a frequency of 13.5%. Symptoms of nasal hyperreactivity involving sneezing, rhinorrhea, nasal obstruction and pruritus were more severe than in other types of rhinitis. The frequency of hyposmia was very specific to NARES. Nasal endoscopy and sinus CT revealed an evolution towards nasal polyposis in four patients. The nasal challenge to house dust mites showed the absence of any increase in local eosinophilia. Bronchial hyperreactivity to carbachol occurred in one case. There was no case of intolerance to aspirin. There was particular adrenergic hyperreactivity among the seven patients, evidenced by study of the reactivity of the cardiovascular alpha and beta receptors. The authors emphasize the features that are shared by NARES and by the triad, which suggest that NARES is the early phase of the triad. They advance the pathogenic hypothesis of an autonomic nervous system dysregulation with a predominating adrenergic hyperreactivity. Inflammatory effects of local release of neurotransmitters induce a switch from a neurogenic to a self-sustaining inflammation. Tissue eosinophilia is regulated by chemical attractants and activating substances of various origins and plays a major part in the chronic inflammatory state.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2346237

Source DB:  PubMed          Journal:  Ann Allergy        ISSN: 0003-4738


  19 in total

Review 1.  Allergic Respiratory Inflammation and Remodeling.

Authors:  Kawa A M Amin
Journal:  Turk Thorac J       Date:  2015-07-01

2.  Prevalence and risk factors of chronic sinusitis in Korea: results of a nationwide survey.

Authors:  Y G Min; H W Jung; H S Kim; S K Park; K Y Yoo
Journal:  Eur Arch Otorhinolaryngol       Date:  1996       Impact factor: 2.503

Review 3.  Pathogenesis of aspirin-exacerbated respiratory disease.

Authors:  Donald D Stevenson; Bruce L Zuraw
Journal:  Clin Rev Allergy Immunol       Date:  2003-04       Impact factor: 8.667

Review 4.  Clinical Evidence of Type 2 Inflammation in Non-allergic Rhinitis with Eosinophilia Syndrome: a Systematic Review.

Authors:  Eugenio De Corso; Veronica Seccia; Giancarlo Ottaviano; Elena Cantone; Daniela Lucidi; Stefano Settimi; Tiziana Di Cesare; Jacopo Galli
Journal:  Curr Allergy Asthma Rep       Date:  2022-02-09       Impact factor: 4.806

Review 5.  Rhinitis in older adults.

Authors:  Sharmilee M Nyenhuis; Sameer K Mathur
Journal:  Curr Allergy Asthma Rep       Date:  2013-04       Impact factor: 4.806

6.  Non-allergic rhinitis: a case report and review.

Authors:  Cyrus H Nozad; L Madison Michael; D Betty Lew; Christie F Michael
Journal:  Clin Mol Allergy       Date:  2010-02-03

Review 7.  Adverse reactions to aspirin and nonsteroidal antiinflammatory drugs (NSAIDs).

Authors:  Ronald A Simon; Jennifer Namazy
Journal:  Clin Rev Allergy Immunol       Date:  2003-06       Impact factor: 8.667

Review 8.  The Role and Immunobiology of Eosinophils in the Respiratory System: a Comprehensive Review.

Authors:  Stephanie S Eng; Magee L DeFelice
Journal:  Clin Rev Allergy Immunol       Date:  2016-04       Impact factor: 8.667

9.  Non-allergic rhinitis with eosinophilia syndrome is not associated with local production of specific IgE in nasal mucosa.

Authors:  Sven Becker; Julia Rasp; Katharina Eder; Alexander Berghaus; Matthias F Kramer; Moritz Gröger
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-09-05       Impact factor: 2.503

10.  A genetic effect of IL-5 receptor α polymorphism in patients with aspirin-exacerbated respiratory disease.

Authors:  Purevsuren Losol; Seung-Hyun Kim; Yoo Seob Shin; Young Min Ye; Hae-Sim Park
Journal:  Exp Mol Med       Date:  2013-03-08       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.